[Anti-GD2 antibodies in treatment of high-risk Neuroblastoma: present and perspectives].
Neuroblastome de haut risque - Place actuelle et perspectives de l’utilisation des anticorps monoclonaux anti-GD2.
Journal
Medecine sciences : M/S
ISSN: 1958-5381
Titre abrégé: Med Sci (Paris)
Pays: France
ID NLM: 8710980
Informations de publication
Date de publication:
Dec 2019
Dec 2019
Historique:
entrez:
7
1
2020
pubmed:
7
1
2020
medline:
23
6
2020
Statut:
ppublish
Résumé
Neuroblastoma is the most frequent extra-cranial pediatric solid tumor, occurring in young children, 90% being less than 5 years at diagnosis. It remains a therapeutic challenge since survival of high-risk neuroblastoma patients that represent around 50% of the patients is around 50% in spite of extensive combined treatments. Immunotherapy based on the use of antibodies directed to GD2, a ganglioside strongly expressed by almost all neuroblastoma cells, has been developed during the last decade. In SIOPEN studies have shown that dinatuximab beta (Qarziba Neuroblastome de haut risque - Place actuelle et perspectives de l’utilisation des anticorps monoclonaux anti-GD2. Le neuroblatome de haut risque reste un défi thérapeutique de l’oncologie pédiatrique puisque qu’il touche de très jeunes patients (90 % ont moins de 5 ans), dont les chances de survie restent inférieures à 50 % malgré des traitements très lourds. Une immunothérapie par l’anticorps monoclonal anti-GD2 dinutuximab bêta (Qarziba
Autres résumés
Type: Publisher
(fre)
Neuroblastome de haut risque - Place actuelle et perspectives de l’utilisation des anticorps monoclonaux anti-GD2.
Identifiants
pubmed: 31903906
doi: 10.1051/medsci/2019197
pii: msc190199
doi:
Substances chimiques
Antibodies, Monoclonal
0
Antineoplastic Agents, Immunological
0
Gangliosides
0
ganglioside, GD2
65988-71-8
Types de publication
Journal Article
Review
Langues
fre
Sous-ensembles de citation
IM
Pagination
997-1000Informations de copyright
© 2019 médecine/sciences – Inserm.
Références
Lacour B, Guyot-Goubin A, Guissou S, et al. Incidence of childhood cancer in France: nnational children cancer registries, 2000–2004. Eur J Cancer Prev 2010 ; 19: 173–181.
Yu AL, Gilman AL, Ozkaynak MF, et al. Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. N Engl J Med 2010 ; 363: 1324–1334.
Ladenstein R, Poetschger U, Valteau-Couanet D, et al. Interleukin 2 with anti-GD2 antibody ch14.18/CHO (dinutuximab beta) in patients with high-risk neuroblastoma (HR-NBL1/SIOPEN): a multicentre, randomised, phase 3 trial. Lancet Oncol 2018 ; 19: 1617–1629.
Lode HN, Valteau-Couanet D, Garaventa A, et al. Long-term infusion of anti-GD2 antibody ch14.18/CHO in combination with interleukin-2 (IL2) activity and efficacy in high-risk relapsed/refractory neuroblastoma patients. J Clin Oncol 2015 ; 33: 10080.
Mueller I, Ehlert K, Endres S, et al. Tolerability, response and outcome of high-risk neuroblastoma patients treated with long-term infusion of anti-GD(2) antibody ch14.18/CHO. MAbs 2018; 10: 55–61.
Ladenstein R, Poetschger U, Valteau-Couanet D, et al. Randomization of dose-reduced subcutaneous interleukin-2 (scIL2) in maintenance immunotherapy (IT) with anti-GD2 antibody dinutuximab beta (DB) long-term infusion (LTI) in front–line high-risk neuroblastoma patients: early results from the HR-NBL1/SIOPEN trial. J Clin Oncol 2019; 37 (abstract 10013).
Ladenstein R, Poetschger U, Valteau-Couanet D, et al. Immunotherapy with anti-GD2 antibody ch14.18/CHO±IL2 within theHR-NBL1/SIOPEN trial improves outcome of high-risk neuroblastoma patients compare to historical controls. J Clin Oncol 2018; 36 (suppl 15): 10539.
Mody R, Naranjo A, Van Ryn C, et al. Irinotecan-temozolomide with temsirolimus or dinutuximab in children with refractory or relapsed neuroblastoma (COG ANBL1221): an open-label, randomised, phase 2 trial. Lancet Oncol 2017 ; 18: 946–957.
Furman WL, Shulkin BL, Federico SM, et al. Early response rates and Curie scores at end of induction: an update from a phase II study of an anti-GD2 monoclonal antibody with chemotherapy in newly diagnosed patients with high-risk neuroblastoma. J Clin Oncol 2017; 35 (abstract 10534).
Terme M, Dorvillius M, Cochonneau D, et al. Chimeric antibody c.8B6 to O-acetyl-GD2 mediates the same efficient anti-neuroblastoma effects as therapeutic ch14.18 antibody to GD2 without antibody induced allodynia. PLoS One 2014 ; 9: e87210.